Australia
Every company in the roster headquartered in Australia.
Every company in the roster headquartered in Australia.
9 of 9 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Actinogen Medical (ASX: ACW)ACW · ASX | 1 asset: 1 Ph 3 | EmestedastatPhase 2/3 · Alzheimer's DiseasePartial signal | None on record | — | — | Ended Aug 2025Jun 2025 | ~$6.0M |
Imugene LimitedIMU · ASX | 1 asset: 1 Ph 1 | Azercabtagene zapreleucelPhase 1 · Multiple Sclerosis | 1 Dec 2026Azercabtagene zapreleucel · Phase 1 | — | — | — | — |
Neuren PharmaceuticalsNEU · ASX | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Radiopharm Theranostics, LtdRADX · Nasdaq | 4 assets: 2 Ph 2, 2 Ph 1 | RAD101Phase 2 · Brain Metastases | Dec 2027RAD202 · Phase 1 | — | $29MJun 2025 | Ended May 2026with a later raise | $28M |
ClinectPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
CSL SeqirusPrivate | 2 assets: 2 approved | Approved assets only | Apr 2027Epinephrine · Approved | — | — | — | — |
| 1 asset: 1 Ph 1 | KS101Phase 1 · Alzheimer's Disease | None on record | — | — | — | — | |
Phebra Pty LtdPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Specialised TherapeuticsPrivate | 1 asset: 1 Ph 3 | PlitidepsinPhase 3 · Multiple MyelomaPartial signal | None on record | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.